Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza® (baloxavir marboxil) for the treatment of acute uncomplicated influenza in otherwise healthy children aged five to less than 12 years of age who have been symptomatic for no more than 48 hours.
Roche announces U.S. FDA approval of Xofluza to treat influenza in children aged five years and older
August 15, 2022
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022